Cancer Research Meeting Calendar  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 47, 5411-5414, October 15, 1987]
© 1987 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tabachnik Schor, N. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tabachnik Schor, N. F.

Adjunctive Use of Ethiofos (WR-2721) with Free Radical-generating Chemotherapeutic Agents in Mice: New Caveats for Therapy

Nina F. Tabachnik Schor1

Departments of Neurology and Biological Chemistry, Harvard Medical School, Boston, Massachusetts 02115

The neurotransmitter analogue 6-hydroxydopamine has been proposed as a selective chemotherapeutic agent for peripheral neural crest tumors. It exerts its action through the generation of cytotoxic oxygen free radicals. Unfortunately, it is toxic to normal peripheral neurons as well. Ethiofos (WR-2721) is a free radical scavenger which appears to be preferentially taken up by normal cells relative to some tumor cells. WR-2721 has been assayed as a protector of the normal autonomic nervous system in mice treated with 6-hydroxydopamine. Although WR-2721 has some activity in this regard, its therapeutic window is narrowed by its depletion of glutathione, a phenomenon which has not previously been noted with this drug. These findings raise issues regarding the safety of adjunctive use of WR-2721 with oxygen free radical-generating chemotherapeutic agents.

1 Supported by a grant from the Ruth Estrin Goldberg Foundation for Cancer Research. Present address: Division of Neurology, Department of Pediatrics, Children's Hospital, University of Pittsburgh, 3705 Fifth Avenue at DeSoto Street, Pittsburgh, PA 15213.

Received 3/13/87. Revised 7/15/87. Accepted 7/21/87.




This article has been cited by other articles:


Home page
J Child NeurolHome page
N. F. Schor
A Neurologist's Approach to Neuroblastoma
J Child Neurol, January 1, 1992; 7(1): 93 - 98.
[Abstract] [PDF]


Home page
J Child NeurolHome page
N. F. Schor
Neuroblastoma: A Neurochemical Approach
J Child Neurol, July 1, 1991; 6(3): 220 - 228.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1987 by the American Association for Cancer Research.